All News
A secondary analysis of the VALOR trial has shown that the TYK2/JAK1 inhibitor brepocitinib was effective at cutaneous disease activity outcomes, delivering rapid, clinically meaningful, and remission-level control of cutaneous dermatomyositis (DM).
This review article addresses the recognition, prevention and management of glucocorticoid toxicity in rheumatic patients.
Dr. Jack Cush reviews the news and journal articles this week where RheumNow featured info on cancer, deadly viruses, AI rules, poetry and good moons rising.
Dr. Jack Cush reviews the news and recent journal reports on RheumNow.com.
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com.
Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.
True or False: In a 6-month RCT for refractory ITP, combining baricitinib with danazol achieved a durable response rate more than double that of danazol monotherapy. Take this week's RheumIQ quiz at https://t.co/yQn8cIT5Cw to see if you got it right! https://t.co/MJSw1gYUob
